Cullinan Therapeutics Reports Positive Early Clinical Data for CLN-978 and Velinotamig in Autoimmune Diseases

summarizeSummary

Cullinan Therapeutics reported positive updated Phase 1 clinical data for CLN-978 in rheumatoid arthritis and systemic lupus erythematosus, alongside promising initial Phase 1b/2a data for velinotamig in refractory SLE, supporting pipeline expansion.

check_boxKey Events

• CLN-978 Shows Robust Efficacy in RA

  Updated Phase 1 OUTRACE RA data demonstrated robust efficacy, including DAS28-ESR remission in a poly-refractory patient previously treated with rituximab, with associated rapid reduction in autoantibodies.

• CLN-978 Promising in SLE Nephritis

  Safety data for CLN-978 in SLE patients were consistent with prior observations, and clinical improvements in SLE patients with nephritis, including rapid reduction in proteinuria, support planned Phase 2a expansion in early 2027 for lupus nephritis.

• Velinotamig Achieves Complete Renal Response in Refractory SLE

  Initial Phase 1b/2a data for velinotamig in two refractory SLE patients showed rapid and marked reductions in SLEDAI-2K scores and proteinuria, with both patients achieving complete renal response and a favorable safety profile.

• Pipeline Expansion and Future Data Readouts

  The company plans to report additional multi-dose CLN-978 data for RA in Q3 2026 and SLE in Q4 2026. For velinotamig, additional data from the China trial is expected in Q4 2026, and a new Phase 1/2a trial in autoimmune cytopenias is planned for Q1 2027.

auto_awesomeAnalysis

Cullinan Therapeutics announced positive early-stage clinical data for two of its T cell engager programs, CLN-978 and velinotamig, in various autoimmune diseases. The data for CLN-978 showed robust efficacy, including clinical remission in a heavily pre-treated rheumatoid arthritis patient and promising observations in systemic lupus erythematosus (SLE) patients with nephritis. Initial data for velinotamig demonstrated rapid and marked clinical improvements, including complete renal responses, in refractory SLE patients. These positive results, particularly in difficult-to-treat patient populations, are crucial for a clinical-stage biopharmaceutical company, potentially enhancing investor confidence and supporting future development and financing efforts, especially given the company's previously reported reduced cash runway.